Organisation paid for research Program year 2025 Source: CMS Open Payments

Patient Priority Clinical Sites LLC

Neither a doctor nor a teaching hospital

Research payments

$3,887,547

343 payments

Through program year 2025, Patient Priority Clinical Sites LLC is reported as receiving $3,887,547 in research payments, across 343 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $411,438 52
2024 Research $271,385 40
2023 Research $253,131 17
2022 Research $765,969 57
2021 Research $767,423 51
2020 Research $849,368 67
2019 Research $568,833 59

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,330,550 16 payments
  2. Sage Therapeutics, Inc. $967,476 91 payments
  3. Allergan Inc. $680,604 94 payments
  4. AbbVie, Inc. $416,505 95 payments
  5. Janssen Research & Development, LLC $347,312 24 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $95,283 6 payments
  7. Sunovion Pharmaceuticals Inc. $49,607 14 payments
  8. Alkermes, Inc. $210 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $656,711 5 payments
  2. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $347,676 3 payments
  3. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $269,142 30 payments
  4. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $249,865 34 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $216,594 23 payments
  6. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $210,978 20 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $206,661 3 payments
  8. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $167,626 28 payments
  9. A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an $163,137 9 payments
  10. 217-Mdd-301 $146,637 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $95,283 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record